T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.

For the adoptive transfer of tumor-directed T lymphocytes to prove effective, there will probably need to be a match between the chemokines the tumor produces and the chemokine receptors the effector T cells express. The Reed-Stemberg cells of Hodgkin lymphoma (HL) predominantly produce thymus- and activation-regulated chemokine/CC chemokine ligand 17 (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22), which preferentially attract type 2 T helper (Th2) cells and regulatory T cells (Tregs) that express the TARC/MDC-specific chemokine receptor CCR4, thus generating an immunosuppressed tumor environment. By contrast, effector CD8(+) T cells lack CCR4, are nonresponsive to these chemokines and are rarely detected at the tumor site. We now show that forced expression of CCR4 by effector T cells enhances their migration to HL cells. Furthermore, T lymphocytes expressing both CCR4 and a chimeric antigen receptor directed to the HL associated antigen CD30 sustain their cytotoxic function and cytokine secretion in vitro, and produce enhanced tumor control when infused intravenously in mice engrafted with human HL. This approach may be of value in patients affected by HL.

[1]  Hao Liu,et al.  Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma , 2008, Nature Medicine.

[2]  S. Bromley,et al.  Orchestrating the orchestrators: chemokines in control of T cell traffic , 2008, Nature Immunology.

[3]  G. T. te Meerman,et al.  Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22 , 2008, British journal of haematology.

[4]  Chung-Che Chang,et al.  Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. , 2007, Blood.

[5]  H. Heslop,et al.  Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. , 2007, Blood.

[6]  C. June,et al.  4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 , 2007, The Journal of Immunology.

[7]  H. Heslop,et al.  Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. , 2007, Blood.

[8]  C. Rooney,et al.  Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. , 2007, Cancer research.

[9]  H. Heslop,et al.  T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. , 2006, Blood.

[10]  S. Iida,et al.  Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. , 2006, Cancer research.

[11]  K. Karube,et al.  Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders , 2006, British Journal of Dermatology.

[12]  H. Heslop,et al.  A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  Mamoru Ito,et al.  Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor‐κB activity in unconditioned NOD/SCID/γcnull mice , 2005 .

[14]  V. Diehl,et al.  Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. , 2005, Cancer research.

[15]  C. Rooney,et al.  Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. , 2005, Blood.

[16]  David D. Smith,et al.  Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. , 2005, Blood.

[17]  Mamoru Ito,et al.  Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice. , 2005, Cancer Science.

[18]  H. Heslop,et al.  Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease , 2004, The Journal of experimental medicine.

[19]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[20]  B. Levine,et al.  In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. , 2004, Blood.

[21]  R. Barker,et al.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. , 2004, Blood.

[22]  F. Marincola,et al.  Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.

[23]  A. Diepstra,et al.  Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical hodgkin lymphomas , 2002, International journal of cancer.

[24]  C. Rooney,et al.  Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. , 2002, Blood.

[25]  Eric J Kunkel,et al.  Chemokines and the tissue-specific migration of lymphocytes. , 2002, Immunity.

[26]  Michel Sadelain,et al.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor , 2002, Nature Biotechnology.

[27]  James J. Campbell,et al.  CC Chemokine Receptor (CCR)4 and the CCR10 Ligand Cutaneous T Cell–attracting Chemokine (CTACK) in Lymphocyte Trafficking to Inflamed Skin , 2001, The Journal of experimental medicine.

[28]  A. Iellem,et al.  Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells , 2001, The Journal of experimental medicine.

[29]  J. Metcalf,et al.  Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. , 2000, Blood.

[30]  L. Avioli,et al.  Hodgkin's disease , 1969, Bone Marrow Transplantation.

[31]  A. van den Berg,et al.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. , 1999, The American journal of pathology.

[32]  A. Mantovani,et al.  Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. , 1998, Journal of immunology.

[33]  S Kimbrough,et al.  Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. , 1998, Blood.

[34]  V. Diehl,et al.  An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. , 1998, Cancer research.

[35]  F. Stirpe,et al.  CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. , 1995, Blood.

[36]  T. Wu,et al.  Detection of ebv gene expression in reed‐sternberg cells of Hodgkin's disease , 1990, International journal of cancer.